A story in the Oct. 25, 2004, issue of BioWorld Today should have said that Dyax Corp. would receive a milestone payment of $10 million if DX-88 is approved by the FDA in an initial indication, HAE, and up to $5 million for each approval in three other therapeutic indications being developed in collaboration with Genzyme Corp.

Editor's Note: The change has been made in BioWorld Online.